Poor glycemic control and decreased renal function are associated with increased intrarenal RAS activity in Type 2 diabetes mellitus

Diabetes Research and Clinical Practice

Volumn 105, Issue 1, 2014, Pages 40-46

  Nakatani, S ^a   Ishimura, E ^a   Naganuma, T ^a   Nakatani, A ^a   Ichii, M ^a   Fukumoto, S ^a   Mori, K ^a   Emoto, M ^a   Nakatani, T ^a   Inaba, M ^a  

^a OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Diabetic nephropathy; Renin angiotensin system; Type 2 diabetes mellitus; Urinary angiotensinogen

Indexed keywords

ALBUMIN; ANGIOTENSINOGEN; CREATININE; GLUCOSE; HEMOGLOBIN A1C;

ADULT; AGE; ARTICLE; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIABETIC NEPHROPATHY; DIET RESTRICTION; FEMALE; GLOMERULUS FILTRATION RATE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SYSTOLIC BLOOD PRESSURE; URINE LEVEL; AGE DISTRIBUTION; AGED; CREATININE URINE LEVEL; DIABETIC PATIENT; DISEASE ASSOCIATION; HEMOGLOBIN BLOOD LEVEL; PROTEIN URINE LEVEL;

DIABETIC NEPHROPATHY; RENIN-ANGIOTENSIN SYSTEM; TYPE 2 DIABETES MELLITUS; URINARY ANGIOTENSINOGEN;

AGED; ANGIOTENSINOGEN; BIOLOGICAL MARKERS; BLOOD GLUCOSE; CASE-CONTROL STUDIES; CREATININE; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; FEMALE; FOLLOW-UP STUDIES; GLOMERULAR FILTRATION RATE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; KIDNEY FUNCTION TESTS; MALE; MIDDLE AGED; RENAL INSUFFICIENCY, CHRONIC; RENIN-ANGIOTENSIN SYSTEM;

EID: 84902551054     PISSN: 01688227     EISSN: 18728227     Source Type: Journal    
DOI: 10.1016/j.diabres.2014.04.019     Document Type: Article

References (34)

1. Ritz E. Limitations and future treatment options in type 2 diabetes with renal impairment. Diabetes Care 2011, 34(Suppl 2):S330-S334.
2. Collins A.J., Foley R.N., Herzog C., Chavers B., Gilbertson D., Ishani A., et al. United States renal data system 2008 annual data report. Am J Kidney Dis 2009, 53:S1-S374.
3. Leehey D.J., Singh A.K., Alavi N., Singh R. Role of angiotensin II in diabetic nephropathy. Kidney Int Suppl 2000, 77:S93-S98.
4. Mann J.F., Schmieder R.E., McQueen M., Dyal L., Schumacher H., Pogue J., et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet 2008, 372:547-553.
5. Yusuf S., Teo K.K., Pogue J., Dyal L., Copland I., Schumacher H., et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008, 358:1547-1559.
6. Dzau V.J., Re R. Tissue angiotensin system in cardiovascular medicine. A paradigm shift?. Circulation 1994, 89:493-498.
7. Silva A.E., Hosein B., Boyle R.W., Fang C.T., Shindo M., Waggoner J.G., et al. Diagnosis of chronic hepatitis C: comparison of immunoassays and the polymerase chain reaction. Am J Gastroenterol 1994, 89:493-496.
8. Dell'Italia L.J., Meng Q.C., Balcells E., Wei C.C., Palmer R., Hageman G.R., et al. Compartmentalization of angiotensin II generation in the dog heart. Evidence for independent mechanisms in intravascular and interstitial spaces. J Clin Invest 1997, 100:253-258.
9. Danser A.H., Admiraal P.J., Derkx F.H., Schalekamp M.A. Angiotensin I-to-II conversion in the human renal vascular bed. J Hypertens 1998, 16:2051-2056.
10. Baltatu O., Silva J.A., Ganten D., Bader M. The brain renin-angiotensin system modulates angiotensin II-induced hypertension and cardiac hypertrophy. Hypertension 2000, 35:409-412.
11. Navar L.G., Kobori H., Prieto-Carrasquero M. Intrarenal angiotensin II and hypertension. Curr Hypertens Rep 2003, 5:135-143.
12. Ingelfinger J.R., Pratt R.E., Ellison K., Dzau V.J. Sodium regulation of angiotensinogen mRNA expression in rat kidney cortex and medulla. J Clin Invest 1986, 78:1311-1315.
13. Kobori H., Harrison-Bernard L.M., Navar L.G. Expression of angiotensinogen mRNA and protein in angiotensin II-dependent hypertension. J Am Soc Nephrol 2001, 12:431-439.
14. Kobori H., Harrison-Bernard L.M., Navar L.G. Enhancement of angiotensinogen expression in angiotensin II-dependent hypertension. Hypertension 2001, 37:1329-1335.
15. Kobori H., Harrison-Bernard L.M., Navar L.G. Urinary excretion of angiotensinogen reflects intrarenal angiotensinogen production. Kidney Int 2002, 61:579-585.
16. Kobori H., Nishiyama A., Harrison-Bernard L.M., Navar L.G. Urinary angiotensinogen as an indicator of intrarenal angiotensin status in hypertension. Hypertension 2003, 41:42-49.
17. Kobori H., Prieto-Carrasquero M.C., Ozawa Y., Navar L.G. AT1 receptor mediated augmentation of intrarenal angiotensinogen in angiotensin II-dependent hypertension. Hypertension 2004, 43:1126-1132.
18. Kobori H., Ohashi N., Katsurada A., Miyata K., Satou R., Saito T., et al. Urinary angiotensinogen as a potential biomarker of severity of chronic kidney diseases. J Am Soc Hypertens 2008, 2:349-354.
19. Mills K.T., Kobori H., Hamm L.L., Alper A.B., Khan I.E., Rahman M., et al. Increased urinary excretion of angiotensinogen is associated with risk of chronic kidney disease. Nephrol Dial Transplant 2012, 27:3176-3181.
20. Ritz E., Dikow R. Hypertension and antihypertensive treatment of diabetic nephropathy. Nat Clin Pract Nephrol 2006, 2:562-567.
21. Peti-Peterdi J., Kang J.J., Toma I. Activation of the renal renin-angiotensin system in diabetes-new concepts. Nephrol Dial Transplant 2008, 23:3047-3049.
22. Singh R., Singh A.K., Alavi N., Leehey D.J. Mechanism of increased angiotensin II levels in glomerular mesangial cells cultured in high glucose. J Am Soc Nephrol 2003, 14:873-880.
23. Fukumoto S., Ishimura E., Motoyama K., Morioka T., Kimoto E., Wakikawa K., et al. Antialbuminuric advantage of cilnidipine compared with L-type calcium channel blockers in type 2 diabetic patients with normoalbuminuria and microalbuminuria. Diabetes Res Clin Pract 2012, 97:91-98.
24. Katsurada A., Hagiwara Y., Miyashita K., Satou R., Miyata K., Ohashi N., et al. Novel sandwich ELISA for human angiotensinogen. Am J Physiol Renal Physiol 2007, 293:F956-F960.
25. Matsuo S., Imai E., Horio M., Yasuda Y., Tomita K., Nitta K., et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis 2009, 53:982-992.
26. Kobori H., Alper A.B., Shenava R., Katsurada A., Saito T., Ohashi N., et al. Urinary angiotensinogen as a novel biomarker of the intrarenal renin-angiotensin system status in hypertensive patients. Hypertension 2009, 53:344-350.
27. Singh R., Alavi N., Singh A.K., Leehey D.J. Role of angiotensin II in glucose-induced inhibition of mesangial matrix degradation. Diabetes 1999, 48:2066-2073.
28. Ikehara K., Tada H., Kuboki K., Inokuchi T. Role of protein kinase C-angiotensin II pathway for extracellular matrix production in cultured human mesangial cells exposed to high glucose levels. Diabetes Res Clin Pract 2003, 59:25-30.
29. Vidotti D.B., Casarini D.E., Cristovam P.C., Leite C.A., Schor N., Boim M.A. High glucose concentration stimulates intracellular renin activity and angiotensin II generation in rat mesangial cells. Am J Physiol Renal Physiol 2004, 286:F1039-F1045.
30. Haneda M., Kikkawa R., Sakai H., Kawamori R. Antiproteinuric effect of candesartan cilexetil in Japanese subjects with type 2 diabetes and nephropathy. Diabetes Res Clin Pract 2004, 66:87-95.
31. Makino H., Haneda M., Babazono T., Moriya T., Ito S., Iwamoto Y., et al. Prevention of transition from incipient to overt nephropathy with telmisartan in patients with type 2 diabetes. Diabetes Care 2007, 30:1577-1578.
32. Uzu T., Sawaguchi M., Maegawa H., Kashiwagi A. Reduction of microalbuminuria in patients with type 2 diabetes: the Shiga Microalbuminuria Reduction Trial (SMART). Diabetes Care 2007, 30:1581-1583.
33. Ruilope L.M., Solini A. RAS blockade for every diabetic patient: pro and con. Diabetes Care 2011, 34(Suppl 2):S320-S324.
34. Brenner B.M., Cooper M.E., de Zeeuw D., Keane W.F., Mitch W.E., Parving H.H., et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001, 345:861-869.